Jeffrey Wiezorek, SVP Clinical Development at Kite Pharma, Inc. (KITE), sold 1,500 shares at $54.72 ($82K) on 2016-10-03, disclosed to the SEC on 2016-10-05.
Open-market sale of $82k KITE by SVP Clinical Development. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $54.72 | 1,330 | $73K | 88.5% |
| 2 | $55.51 | 170 | $9K | 11.5% |
| Total | $54.81 avg | 1,500 | $82K | 100% |
| Filing → |
| KITE | SELL | 2017-03-02 | $1.4M | — | Filing → |
| KITE | SELL | 2017-02-06 | $77K | — | Filing → |
| KITE | SELL | 2017-01-10 | $75K | — | Filing → |